Stockreport

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Relmada Therapeutics, Inc.  (RLMD) 
NASDAQ:AMEX Investor Relations: ir.relmada.com
PDF Outcome of pre-planned Reliance II interim analysis anticipated by YE 2024 Enrollment in Phase 3 Reliance II study expected to be completed by YE 2024 Preparations on [Read more]